台灣臨床試驗主持人資料庫|TPIDB

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol Number201637

2015-06-01 - 2021-12-31

Phase III

Terminated4

ICD-10B20

Human immunodeficiency virus [HIV] disease

ICD-9042

Human immunodeficiency virus（HIV）infection disease

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed

Sponsor
Trial scale

Multi-Regional Multi-Center
Update

2025/08/20

Investigators and Locations

Principal Investigator YU-HUI LIN Division of Infectious Disease

Taichung Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Hsi-Hsun Lin Division of Infectious Disease

E-DA Hospital

Co-Principal Investigator

黃俊凱 Division of Infectious Disease
楊素盆 Division of Infectious Disease

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator 楊家瑞 Division of Infectious Disease

Far Eastern Memorial Hospital

Co-Principal Investigator

蔡茂松 Division of Infectious Disease
劉佳穎 Division of Infectious Disease

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Principal Investigator Jih-Jin Tsai Division of Infectious Disease

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Stop recruiting

Condition/Disease

HIV-1-Infected Adults

Objectives

Test Drug

Dolutegravir, Rilpivirine

Active Ingredient

Dolutegravir
Rilpivirine

Dosage Form

Dosage

25
50

Endpoints

Inclution Criteria

Exclusion Criteria

The Estimated Number of Participants

Taiwan

30 participants
Global

680 participants